Cannabis Bioscience International Holdings, Inc. (CBIH)
OTCMKTS · Delayed Price · Currency is USD
0.0004
0.00 (0.00%)
Mar 30, 2026, 9:30 AM EST
CBIH Revenue
Cannabis Bioscience International Holdings had revenue of $53.27K in the quarter ending November 30, 2025, a decrease of -28.26%. This brings the company's revenue in the last twelve months to $127.35K, down -65.15% year-over-year. In the fiscal year ending May 31, 2025, Cannabis Bioscience International Holdings had annual revenue of $303.02K with 21.77% growth.
Revenue (ttm)
127.35K
Revenue Growth
-65.15%
P/S Ratio
36.52
Revenue / Employee
63.68K
Employees
2
Market Cap
4.65M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| May 31, 2025 | 303.02K | 54.18K | 21.77% |
| May 31, 2024 | 248.84K | -67.98K | -21.46% |
| May 31, 2023 | 316.83K | 101.85K | 47.37% |
| May 31, 2022 | 214.98K | -546.76K | -71.78% |
| May 31, 2021 | 761.74K | 471.50K | 162.46% |
| May 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Eagle Pharmaceuticals | 257.55M |
| Trees | 14.50M |
| CV Sciences | 13.79M |
| CordovaCann | 10.25M |
| SOHM, Inc. | 1.30M |
| Rafarma Pharmaceuticals | 133.33K |
| Indo Global Exchange(s) PTE | 3.49K |
Cannabis Bioscience International Holdings News
- 2 months ago - CBIH Puts CMS at the Center of the Board: Formal Coordination with Dr. Mehmet Oz's Team and an "Evidence Sprint 2026" Focused on Grants, Research and Clinical Evidence - Newsfile Corp
- 3 months ago - CBIH Launches Federal and Pharmaceutical Outreach Initiative to Accelerate Medical Cannabis Research in the Schedule III Transition - Newsfile Corp
- 3 months ago - CBIH Announces New Patent Initiative Targeting Opioid Addiction Through Endocannabinoid Pathways - Newsfile Corp
- 3 months ago - CBIH Welcomes Federal Momentum Toward Cannabis Rescheduling as 2026 Opens a New Window to Accelerate Medical Innovation and Growth, with CBIH Positioned to Capitalize on Emerging Opportunities - Newsfile Corp
- 6 months ago - CBIH Announces Women-First Fertility Innovation Built on Nanoemulsion Delivery - Newsfile Corp
- 6 months ago - CBIH Ignites Texas: Statewide TCUP Seminar Marks a New Era for Medical Cannabis-With Evidence, Safety, and Patient Dignity at the Center - Newsfile Corp
- 1 year ago - CBIH Welcomes Charles Tamburello to Its Board, Strengthening M&A Strategy - Newsfile Corp
- 1 year ago - CBIH Strengthens Competitive Advantage with Rapid Expansion of Patent Filings - Newsfile Corp